SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Advanced Viral Research CP (ADVR)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Oak Tree who wrote (695)8/20/1996 11:44:00 PM
From: Bernie Bildman   of 2281
 
Paul, hate to disagree with you. Last time around it WAS the Barrons article that tanked it. And last time around the S-1 just released had not been seen. It basically lays out ALL the pitfalls and the past history of the company. There is nothing in the closet left to throw around. This stock has seen the last of .50 prices.

As far as the study done by Hirschman, all that was seen and released was a poster presentation that was brief. This paper is much more detailed insofar as to how the drug Reticulose works. The fact that the JIM has picked it up to be published (along with peer review) lends credence to the premise of the claims of the testing.

You will be sorry you sold at THIS point, and short selling will only make you have to buy back at a HIGHER price the shares you sell short.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News